Patents by Inventor Sayantani Sarkar

Sayantani Sarkar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds as PRMT5 inhibitors
    Patent number: 11459338
    Abstract: The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: October 4, 2022
    Assignee: JUBILANT EPISCRIBE LLC
    Inventors: Saravanan Vadivelu, Sridharan Rajagopal, Raghunadha Reddy Burri, Shivani Garapaty, Dhanalakshmi Sivanandhan, Manish Kumar Thakur, Tamizharasan Natarajan, Indu N Swamy, Nagendra Nagaraju, Subramaniam Kanagaraj, Zainuddin Mohd, Sayantani Sarkar, Swapan Kumar Samanta, Hariprakash
  • HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
    Publication number: 20210371431
    Abstract: The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.
    Type: Application
    Filed: November 23, 2018
    Publication date: December 2, 2021
    Inventors: Saravanan VADIVELU, Sridharan RAJAGOPAL, Raghunadha Reddy BURRI, Shivani GARAPATY, Dhanalakshmi SIVANANDHAN, Manish Kumar THAKUR, Tamizharasan NATARAJAN, Indu N SWAMY, Nagendra NAGARAJU, Subramaniam KANAGARAJ, Zainuddin MOHD, Sayantani SARKAR, Swapan Kumar SAMANTA, Hariprakash N/A
  • Process for the isolation of organic compounds useful for the treatment of cancer
    Patent number: 8637679
    Abstract: The present invention relates to two main components, mahanine and mahanimbine (dehydroxy-mahanine) from Murraya koenigii for the treatment of glioblastoma and cervical carcinoma. Mahanimbine exhibited anti-cancer activity against lymphoid leukemia, myeloid leukemia, glioma, cervical carcinoma, pancreatic, colon and lung cancers in nineteen cells of different genetic status. C-3 hydroxy and NH groups are responsible contributing groups for their cytotoxicity. Mahanine reduced the doses of cisplatin and paclitaxel in cervical cancer showing better efficacy and useful as an adjunct chemotherapeutic agent to reduce toxicity these two drugs. A new cheap process for this preparation was established. EtOAc extract containing alkaloids enriched with mahanimbine and mahanine, is active against glioma and cervical cancers.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: January 28, 2014
    Assignee: Council of Scientific and Industrial Research
    Inventors: Chitra Mandal, Bikas Chandra Pal, Kaushik Bhattacharya, Suman Kumar Samanta, Sayantani Sarkar, Ranjita Das
  • PROCESS FOR THE ISOLATION OF ORGANIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER
    Publication number: 20130065932
    Abstract: The present invention relates to two main components, mahanine and mahanimbine (dehydroxy-mahanine) from Murraya koenigii for the treatment of glioblastoma and cervical carcinoma. Mahanimbine exhibited anti-cancer activity against lymphoid leukemia, myeloid leukemia, glioma, cervical carcinoma, pancreatic, colon and lung cancers in nineteen cells of different genetic status. C-3 hydroxy and NH groups are responsible contributing groups for their cytotoxicity. Mahanine reduced the doses of cisplatin and paclitaxel in cervical cancer showing better efficacy and useful as an adjunct chemotherapeutic agent to reduce toxicity these two drugs. A new cheap process for this preparation was established. EtOAc extract containing alkaloids enriched with mahanimbine and mahanine, is active against glioma and cervical cancers.
    Type: Application
    Filed: March 9, 2012
    Publication date: March 14, 2013
    Applicant: Council of Scientific and Industrial Research
    Inventors: Chitra Mandal, Bikas Chandra Pal, Kaushik Bhattacharya, Suman Kumar Samanta, Sayantani Sarkar, Ranjita Das